Cellectar Biosc (CLRB) Stock Price, Quote & News

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology

Sector: Healthcare

Phone: 608 441 8120

Website: www.cellectar.com

Address:

100 Campus Drive, Florham Park, United States

szcyxzh Oct. 4 at 4:20 PM

$CLRB FDA should watch this President Trump's meeting with pediatric cancer patients and grants immediate conditional approval for CLRB's 131 line. https://www.youtube.com/watch?v=bTRpf0jJODg

0 · Reply

RadioIsotope25 Oct. 4 at 2:04 PM

Inside Cancer Innovation Radiopharmaceuticals RADX What’s Next - YouTube $PSTV $CLRB $ATNM https://www.youtube.com/watch?v=df1JoFcU7gA

0 · Reply

MSG8898 Oct. 4 at 12:43 PM

$CLRB I bet ya'll know where this's gonna be next week!

0 · Reply

EvenBetter99 Oct. 3 at 8:46 PM

$CLRB ready to go back to USD 55.00 🚀🚀🚀

0 · Reply

Vikingsstrade Oct. 3 at 7:26 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $SBLX $BREA $JDZG $CLRB

0 · Reply

scales324 Oct. 3 at 4:13 PM

$CLRB this is gonna SCREAM with volume!! lol

1 · Reply

scales324 Oct. 3 at 2:16 PM

$CLRB this one is TOTALLY setting up... now is the time to get in before volume hits and low float!

0 · Reply

S2K_TP Oct. 3 at 7:59 AM

$CLRB 12%⬆️ setting up 🌋🔥

0 · Reply

MoonCowBoy Oct. 3 at 12:33 AM

$CLRB $TRUG $STEM $SLE

0 · Reply

scales324 Oct. 2 at 7:48 PM

$RZLV is awesome and want to be REALLY early on something? $CLRB is about to get an approval IMHO... slowly waking up.. LOW float and LOW LOW volume now

0 · Reply

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Sep 9, 2025, 8:05 AM EDT - 25 days ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Sep 5, 2025, 8:45 AM EDT - 4 weeks ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Sep 3, 2025, 8:05 AM EDT - 4 weeks ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Aug 27, 2025, 8:05 AM EDT - 5 weeks ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Aug 14, 2025, 12:25 PM EDT - 7 weeks ago

Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:19 AM EDT - 7 weeks ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 7, 2025, 8:05 AM EDT - 2 months ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Jul 2, 2025, 4:15 PM EDT - 3 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 1, 2025, 9:25 AM EDT - 3 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jun 26, 2025, 8:05 AM EDT - 3 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 24, 2025, 8:30 AM EDT - 3 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 18, 2025, 4:30 PM EDT - 3 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

$Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma$

Jun 11, 2025, 8:05 AM EDT - 4 months ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 5, 2025, 9:00 AM EDT - 4 months ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 4, 2025, 8:05 AM EDT - 4 months ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

May 13, 2025, 2:17 PM EDT - 5 months ago

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 5 months ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 7, 2025, 8:05 AM EDT - 5 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Apr 30, 2025, 8:05 AM EDT - 5 months ago

Cellectar Announces Plan to Explore Strategic Alternatives

Mar 13, 2025, 12:41 PM EDT - 7 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:05 AM EDT - 7 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 5, 2025, 8:05 AM EST - 7 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Feb 5, 2025, 8:05 AM EST - 8 months ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 12, 2025, 6:00 PM EST - 9 months ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Dec 11, 2024, 11:25 AM EST - 10 months ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 10, 2024, 5:00 PM EST - 10 months ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Nov 21, 2024, 8:00 AM EST - 11 months ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 18, 2024, 10:59 AM EST - 11 months ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 7:05 AM EST - 11 months ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 14, 2024, 8:05 AM EST - 11 months ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 12, 2024, 8:05 AM EST - 11 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 11, 2024, 4:05 PM EST - 11 months ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 7, 2024, 6:40 AM EST - 11 months ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 1, 2024, 5:00 PM EDT - 1 year ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Aug 26, 2024, 6:40 AM EDT - 1 year ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 13, 2024, 1:25 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 8, 2024, 5:15 PM EDT - 1 year ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Jul 24, 2024, 3:22 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 23, 2024, 3:09 PM EDT - 1 year ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 10:49 AM EDT - 1 year ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 22, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jun 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

May 29, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 20, 2024, 1:02 PM EDT - 1 year ago

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

May 14, 2024, 1:05 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

szcyxzh Oct. 4 at 4:20 PM

$CLRB FDA should watch this President Trump's meeting with pediatric cancer patients and grants immediate conditional approval for CLRB's 131 line. https://www.youtube.com/watch?v=bTRpf0jJODg

0 · Reply

RadioIsotope25 Oct. 4 at 2:04 PM

Inside Cancer Innovation Radiopharmaceuticals RADX What’s Next - YouTube $PSTV $CLRB $ATNM https://www.youtube.com/watch?v=df1JoFcU7gA

0 · Reply

MSG8898 Oct. 4 at 12:43 PM

$CLRB I bet ya'll know where this's gonna be next week!

0 · Reply

EvenBetter99 Oct. 3 at 8:46 PM

$CLRB ready to go back to USD 55.00 🚀🚀🚀

0 · Reply

Vikingsstrade Oct. 3 at 7:26 PM

0 · Reply

scales324 Oct. 3 at 4:13 PM

$CLRB this is gonna SCREAM with volume!! lol

1 · Reply

scales324 Oct. 3 at 2:16 PM

$CLRB this one is TOTALLY setting up... now is the time to get in before volume hits and low float!

0 · Reply

S2K_TP Oct. 3 at 7:59 AM

$CLRB 12%⬆️ setting up 🌋🔥

0 · Reply

MoonCowBoy Oct. 3 at 12:33 AM

$CLRB $TRUG $STEM $SLE

0 · Reply

scales324 Oct. 2 at 7:48 PM

$RZLV is awesome and want to be REALLY early on something? $CLRB is about to get an approval IMHO... slowly waking up.. LOW float and LOW LOW volume now

0 · Reply

1Spartantrade1 Oct. 2 at 6:33 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $JDZG $CLRB $TRUG $STEM 🔥

0 · Reply

Siuolman58 Oct. 1 at 6:32 PM

$CLRB Float is way low! Only3M. Time to blast off

0 · Reply

szcyxzh Oct. 1 at 3:59 PM

$CLRB While everyone here seems bullish, and others are bullish to 7,000 SPX, my concern is how messy it will be when SPX corrects 15% first. One thing for sure is that there will be no immunity in this market if there were an upcoming major correction.

0 · Reply

DM0n3y Oct. 1 at 2:30 PM

$CLRB partnership news and we go to 20

0 · Reply

EvenBetter99 Oct. 1 at 4:32 AM

$CLRB Pretty nice chances with Iopofosine in many multi billion markets. Innovative radiotargeted therapies like PDC MOA are the new way in oncology.

0 · Reply

Siuolman58 Sep. 30 at 7:52 PM

$CLRB Wow great news for these tough cancers! Just think what will happen with volume!

0 · Reply

higgggghhhher Sep. 30 at 4:22 PM

$CLRB this interim data is unbelievably good. Will have full data around same time as the btki data. Only reason you can say fda won’t accelerate approve this is sample size. FDA is clearly saying they will approve for rare disease at this stage if it’s a mechanism with long term data and it’s safe.

1 · Reply

Siuolman58 Sep. 30 at 1:19 PM

$CLRB https://investor.cellectar.com/press-releases/detail/375/cellectar-biosciences-presented-compelling-data-in-oral

0 · Reply

ObsOlet Sep. 30 at 6:33 AM

$CLRB https://stockstoday.com/cellectar-biosciences-faces-pivotal-week-with-dual-catalysts/?utm_source=Ad-Hoc-News

0 · Reply

Siuolman58 Sep. 29 at 6:08 PM

$CLRB 🔥 $CLRB is heating up! 🔥 Low float + breakthrough oncology play = 🚀 When Wall Street wakes up, this won’t stay under the radar. Next big runner loading… 💥 #Biotech #Moonshot #PennyStocks

0 · Reply

Siuolman58 Sep. 29 at 6:03 PM

$CLRB $67.50 high and a sleeper for sure. Will breakout to the stratosphere on High volume. Low low float with great results on Cancers. this can fly at any moment!

1 · Reply

DM0n3y Sep. 29 at 11:18 AM

$CLRB big PR coming

0 · Reply

Market Cap	16.84M
Revenue (ttm)	0.00
Net Income (ttm)	-44.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,765,327
Avg Vol	14,877,256
Day's Range	N/A - N/A
Shares Out	46.08M
Stochastic %K	31%
Beta	0.52
Analysts	Sell
Price Target	$4.00